CELZHealthcare · BiotechnologyThe 1 Wall Street analysts covering Creative Medical Technology Holdings, Inc. hold a median 12-month price target of $20 — +1539.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 13 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Creative Medical Technology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Value (3): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CELZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1539.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Feb 2022 | Roth Capital | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELZ appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 1% of US stocks
Cheaper than 75% of US stocks
Cheaper than 60% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Creative Medical Technology Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares surged Thursday afternoon following an intellectual property milestone related to a key patent win.
Why it matters — A key patent win represents an intellectual property milestone for CELZ that could affect the company's competitive position.
Creative Medical Technology Holdings, Inc. announced it received a notice of allowance for a new U.S. patent covering exosome-based immunotherapy for type 1 diabetes. The patent protects the cell-free MyeloCelz™ exosome technology, which is designed to suppress autoimmune destruction of insulin-producing cells, and deepens IP protection across the company's MyeloCelz™, CELZ-101 and CELZ-201 diabetes platforms.
Why it matters — A CELZ watcher would care because the newly allowed patent strengthens the company's intellectual property protection across its multi-program diabetes strategy, supporting its cell-free exosome technology.
The 1 Wall Street analysts covering Creative Medical Technology Holdings, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Creative Medical Technology Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Creative Medical Technology Holdings, Inc. 20 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Creative Medical Technology Holdings, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1539.3% from the last close, and Ticker Nerd's factor model ranks Creative Medical Technology Holdings, Inc. 20 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Creative Medical Technology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
Creative Medical Technology Holdings, Inc. returned -60.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Creative Medical Technology Holdings Inc. is a clinical- and commercial-stage biotechnology company specializing in regenerative medicine and immunotherapy.
The most recent item we track (Benzinga, 6 Aug 2026): "Creative Medical Technology Stock Surges After Key Patent Win". Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares surged Thursday afternoon following an intellectual property milestone related to a key patent win.
Creative Medical Technology Holdings Inc. is a clinical- and commercial-stage biotechnology company specializing in regenerative medicine and immunotherapy. The company focuses on stem cell–based therapies addressing unmet needs across orthopedics, endocrinology, immunology, urology, and gynecology. Its pipeline includes proprietary platforms such as Olastrocel, a leading allogeneic cell therapy candidate for chronic lower back pain and metabolic indications, as well as ImmCelz, a personalized immune cell technology designed to modulate immune responses. Creative Medical Technology Holdings Inc. also develops and commercializes procedures and products for sexual health and infertility, including applications for erectile dysfunction, female sexual dysfunction, and premature ovarian failure. Headquartered in Phoenix, Arizona and founded in 1998, the company operates through multiple cell-based platforms using adult and perinatal stem cell technologies, aiming to deliver clinically validated regenerative treatments to patients via physician networks and specialized clinical programs.
CEO Mr. Timothy Warbington · 4 employees · United States · https://www.creativemedicaltechnology.com